Lexaria Bioscience (OTCMKTS:LXRP) and U.S. Gold (NASDAQ:USAU) Critical Survey

U.S. Gold (NASDAQ:USAU) and Lexaria Bioscience (OTCMKTS:LXRP) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for U.S. Gold and Lexaria Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
U.S. Gold	0	0	2	1	3.33
Lexaria Bioscience	0	0	0	0	0.00

U.S. Gold presently has a consensus target price of $11.50, indicating a potential upside of 19.29%. Given U.S. Gold’s stronger consensus rating and higher probable upside, equities research analysts plainly believe U.S. Gold is more favorable than Lexaria Bioscience.

Insider & Institutional Ownership

6.6% of U.S. Gold shares are held by institutional investors. Comparatively, 0.1% of Lexaria Bioscience shares are held by institutional investors. 11.1% of U.S. Gold shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares U.S. Gold and Lexaria Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
U.S. Gold	N/A	N/A	-$6.90 million	($1.36)	-7.09
Lexaria Bioscience	$380,000.00	0.00	-$4.09 million	N/A	N/A

Lexaria Bioscience has higher revenue and earnings than U.S. Gold.

Profitability

This table compares U.S. Gold and Lexaria Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
U.S. Gold	N/A	-59.61%	-42.24%
Lexaria Bioscience	-1,046.77%	-157.62%	-148.09%

Summary

U.S. Gold beats Lexaria Bioscience on 9 of the 11 factors compared between the two stocks.

About U.S. Gold

U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project located in Eureka County, Nevada. The company was formerly known as Dataram Corporation and changed its name to U.S. Gold Corp. in June 2017. U.S. Gold Corp. is based in Elko, Nevada.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.